Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
11.15
Dollar change
-0.26
Percentage change
-2.28
%
IndexRUT P/E- EPS (ttm)-3.74 Insider Own45.78% Shs Outstand49.95M Perf Week-10.87%
Market Cap559.17M Forward P/E- EPS next Y-2.73 Insider Trans-0.05% Shs Float27.19M Perf Month-23.16%
Income-160.81M PEG- EPS next Q-0.82 Inst Own57.89% Short Float10.72% Perf Quarter-25.02%
Sales0.00M P/S- EPS this Y14.60% Inst Trans1.06% Short Ratio7.90 Perf Half Y134.24%
Book/sh3.80 P/B2.94 EPS next Y14.38% ROA-58.58% Short Interest2.91M Perf Year128.95%
Cash/sh3.64 P/C3.06 EPS next 5Y- ROE-70.97% 52W Range3.94 - 17.42 Perf YTD-25.12%
Dividend Est.- P/FCF- EPS past 5Y-50.98% ROI-78.31% 52W High-35.99% Beta1.59
Dividend TTM- Quick Ratio5.24 Sales past 5Y-8.67% Gross Margin- 52W Low183.30% ATR (14)1.00
Dividend Ex-Date- Current Ratio5.24 EPS Y/Y TTM-23.35% Oper. Margin0.00% RSI (14)37.45 Volatility6.87% 7.95%
Employees72 Debt/Eq0.09 Sales Y/Y TTM- Profit Margin- Recom1.29 Target Price20.17
Option/ShortYes / Yes LT Debt/Eq0.08 EPS Q/Q-23.17% Payout- Rel Volume3.21 Prev Close11.41
Sales Surprise- EPS Surprise-6.08% Sales Q/Q- EarningsMar 07 AMC Avg Volume368.64K Price11.15
SMA20-13.68% SMA50-20.97% SMA20017.46% Trades Volume1,184,748 Change-2.28%
Date Action Analyst Rating Change Price Target Change
Mar-08-24Downgrade Stifel Buy → Hold $10 → $14
Dec-08-23Upgrade Jefferies Hold → Buy $8 → $18
Dec-22-21Downgrade Jefferies Buy → Hold $65 → $25
Sep-30-21Initiated Stifel Buy $106
May-05-21Resumed Credit Suisse Outperform $98
Apr-26-21Resumed Credit Suisse Outperform $98
Apr-06-21Initiated UBS Buy
Feb-10-21Initiated H.C. Wainwright Buy $100
Aug-11-20Initiated Piper Sandler Overweight $55
Aug-11-20Initiated Jefferies Buy $50
Mar-08-24 03:48PM
Mar-07-24 10:53PM
10:41PM
04:03PM
Mar-05-24 04:30PM
08:00AM Loading…
Jan-03-24 08:00AM
Dec-22-23 04:21PM
Nov-13-23 04:47PM
04:05PM
Nov-01-23 04:05PM
Oct-10-23 04:05PM
Oct-06-23 04:59AM
Oct-05-23 10:58AM
08:00AM
Oct-04-23 04:10PM
11:39AM Loading…
11:39AM
Oct-03-23 11:15AM
09:36AM
06:00AM
Oct-02-23 04:05PM
Sep-06-23 08:00AM
Aug-31-23 07:00AM
Aug-14-23 07:31PM
Aug-10-23 04:01PM
09:55AM
Jun-26-23 07:00AM
May-11-23 04:01PM
May-09-23 07:00AM
Apr-25-23 07:00AM
Apr-19-23 11:36AM
08:00AM Loading…
Mar-14-23 08:00AM
Mar-13-23 07:00AM
Mar-09-23 04:01PM
Feb-16-23 07:00AM
Jan-05-23 07:00AM
Jan-03-23 07:00AM
Dec-12-22 10:00AM
Nov-29-22 07:00AM
Nov-08-22 04:01PM
Nov-03-22 09:00AM
Nov-02-22 07:00AM
Oct-31-22 07:00AM
Oct-05-22 08:01AM
Sep-21-22 04:01PM
Sep-01-22 07:00AM
Aug-16-22 09:45AM
Aug-15-22 07:00AM
Aug-11-22 07:00AM
Aug-08-22 04:01PM
Aug-01-22 07:00AM
Jun-29-22 08:44AM
07:00AM
Jun-22-22 09:00AM
Jun-03-22 07:00AM
Jun-01-22 07:00AM
Apr-12-22 07:00AM
Mar-02-22 07:00AM
Feb-28-22 07:00AM
Feb-03-22 07:01PM
Feb-02-22 01:38PM
Jan-28-22 12:44PM
08:02AM
Jan-27-22 05:51PM
Jan-19-22 06:23AM
Jan-10-22 06:00AM
Jan-04-22 07:00AM
Dec-14-21 09:00AM
Dec-13-21 01:58PM
Dec-12-21 09:00AM
Nov-11-21 04:05PM
Nov-09-21 11:13AM
07:00AM
Nov-04-21 09:00AM
Nov-02-21 09:00AM
Oct-21-21 11:19AM
07:00AM
Oct-07-21 07:00AM
Oct-01-21 08:00AM
Sep-16-21 07:00AM
Sep-14-21 07:00AM
Sep-07-21 07:00AM
Aug-27-21 06:55AM
Aug-12-21 04:05PM
Jul-28-21 07:00AM
Jul-15-21 12:00PM
01:36AM
Jul-12-21 06:07AM
Jul-06-21 09:15AM
Jul-03-21 07:15AM
Jun-14-21 07:00AM
Jun-10-21 07:00AM
May-18-21 07:00AM
May-17-21 04:05PM
May-10-21 07:00AM
Apr-21-21 04:05PM
Apr-16-21 01:41AM
Apr-05-21 07:00AM
Mar-18-21 04:05PM
Mar-15-21 07:00AM
Mar-05-21 08:15AM
ALX Oncology Holdings, Inc. operates as a clinical stage company, which engages in the research and development of therapies for cancer patients. Its objective is to provide clinical therapies for the treatment of myelodysplastic syndromes, acute myeloid leukemia, and a range of solid tumor indications. The company was founded by Corey Goodman, Jaume Pons, and K. Christopher Garcia in March 2015 and is headquartered in South San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lettmann JasonCHIEF EXECUTIVE OFFICERMar 14 '24Buy11.314,40049,771171,620Mar 18 04:06 PM
Pinto ShellySVP, Finance and CAOJan 04 '24Sale13.602,71736,95778,591Jan 05 04:03 PM
Pons JaumePresident & CSODec 29 '23Sale15.047,179107,972618,359Jan 03 04:17 PM
Randolph SophiaChief Medical OfficerDec 29 '23Sale15.043,12847,045312,349Jan 03 04:25 PM
GARCIA PETER SChief Financial OfficerDec 29 '23Sale15.041,89328,47185,348Jan 03 04:20 PM
Pinto ShellySVP, Finance and CAODec 29 '23Sale15.041,63124,53081,308Jan 03 04:28 PM
Pinto ShellyVP, Finance and CAOJul 06 '23Sale6.527,34547,88955,713Jul 07 04:09 PM
Pons JaumePresident & CEOJun 30 '23Sale7.343,20823,547536,538Jul 05 05:07 PM
Randolph SophiaChief Medical OfficerJun 30 '23Sale7.341,60511,781281,477Jul 05 05:09 PM
GARCIA PETER SChief Financial OfficerJun 30 '23Sale7.348876,51154,738Jul 05 05:00 PM
Pinto ShellyVP, Finance and CAOJun 30 '23Sale7.344663,42063,058Jul 05 05:05 PM
Randolph SophiaChief Medical OfficerJun 09 '23Option Exercise3.7512,82948,171283,082Jun 13 04:38 PM